[ALDX] Aldeyra Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart ALDX

Refresh chart

Strongest Trends Summary For ALDX

ALDX is in the long-term down -64% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company?s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-1.91 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.25
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.5% ROE-55.88% ROI
Current Ratio15.35 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.04 M Cash From Investing Activities Cash From Operating Activities-1.84 M Gross Profit
Net Profit-2.14 M Operating Profit-2.11 M Total Assets15.93 M Total Current Assets15.9 M
Total Current Liabilities1.04 M Total Debt1.26 M Total Liabilities2.1 M Total Revenue
Technical Data
High 52 week14.35 Low 52 week5.16 Last close5.21 Last change-3.52%
RSI47.88 Average true range0.3 Beta0.82 Volume13.12 K
Simple moving average 20 days-3.59% Simple moving average 50 days-13.96% Simple moving average 200 days-34.81%
Performance Data
Performance Week-4.23% Performance Month-9.08% Performance Quart-32.77% Performance Half-34.22%
Performance Year-27.13% Performance Year-to-date-37.23% Volatility daily2.49% Volatility weekly5.56%
Volatility monthly11.39% Volatility yearly39.45% Relative Volume214.91% Average Volume253.42 K
New High New Low

News

2019-11-14 13:08:53 | Edited Transcript of ALDX earnings conference call or presentation 7-Nov-19 1:00pm GMT

2019-11-12 08:00:00 | Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

2019-11-07 07:00:00 | Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

2019-11-01 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update

2019-10-31 07:00:00 | Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

2019-10-30 16:01:00 | Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

2019-10-21 08:02:11 | Does The Aldeyra Therapeutics, Inc. NASDAQ:ALDX Share Price Fall With The Market?

2019-10-13 16:33:09 | The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

2019-10-07 08:00:00 | Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting

2019-09-26 08:00:00 | Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting

2019-09-25 08:00:00 | Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference

2019-09-24 08:00:00 | Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

2019-09-12 02:15:02 | Aldeyra Therapeutics Inc ALDX President and CEO Todd C Brady Bought $102,800 of Shares

2019-09-06 11:18:46 | What Kind Of Shareholder Appears On The Aldeyra Therapeutics, Inc.'s NASDAQ:ALDX Shareholder Register?

2019-08-28 08:30:00 | Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

2019-08-11 05:01:33 | Edited Transcript of ALDX earnings conference call or presentation 8-Aug-19 12:00pm GMT

2019-08-09 18:56:01 | Aldeyra Therapeutics Inc ALDX Q2 2019 Earnings Call Transcript

2019-08-08 07:00:00 | Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-05 12:29:51 | Here’s What Hedge Funds Think About Aldeyra Therapeutics Inc ALDX

2019-07-01 12:55:23 | 7 Stocks on Sale the Insiders Are Buying

2019-06-25 09:26:14 | No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

2019-06-25 07:39:00 | Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

2019-06-25 07:00:00 | Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis

2019-06-24 16:30:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis

2019-05-30 08:00:00 | Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference

2019-05-09 16:54:57 | Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT

2019-05-09 15:23:50 | Aldeyra Therapeutics Inc ALDX Q1 2019 Earnings Call Transcript

2019-05-09 07:00:00 | Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-02 08:00:00 | Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

2019-04-30 08:00:00 | Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial

2019-04-09 08:00:00 | Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology ARVO Annual Meeting

2019-04-02 08:00:00 | Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease

2019-03-27 17:09:09 | Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

2019-03-27 10:00:00 | Future Brightens for 2 Small Biotech Stocks

2019-03-26 13:14:03 | Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

2019-03-26 11:57:44 | Aldeyra stock jumps 50 percent after eye allergy trial success

2019-03-26 10:37:41 | Aldeyra's eye drug meets main goal in late-stage study, shares surge

2019-03-26 09:41:40 | Should Aldeyra Therapeutics NASDAQ:ALDX Be Disappointed With Their 68% Profit?

2019-03-26 07:51:00 | Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints

2019-03-26 07:00:00 | Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

2019-03-25 16:01:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

2019-03-13 10:35:02 | Options Traders Expect Huge Moves in Aldeyra ALDX Stock

2019-03-08 12:12:00 | Aldeyra Therapeutics Inc ALDX Q4 2018 Earnings Conference Call Transcript

2019-03-08 12:04:13 | Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT

2019-03-08 07:00:00 | Aldeyra Therapeutics Announces Year-End 2018 Financial Results

2019-03-01 08:00:00 | Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019

2019-02-28 07:00:00 | Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day

2019-02-12 08:00:00 | Aldeyra Therapeutics to Host 2019 Research & Development Day

2019-01-30 07:55:00 | Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-29 08:00:00 | Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision